Log in

NASDAQ:FLDM - Fluidigm Stock Price, Forecast & News

$3.84
+0.09 (+2.40 %)
(As of 02/23/2020 03:28 AM ET)
Today's Range
$3.68
Now: $3.84
$3.85
50-Day Range
$3.31
MA: $3.79
$4.35
52-Week Range
$2.12
Now: $3.84
$14.90
Volume336,535 shs
Average Volume603,811 shs
Market Capitalization$267.15 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.24 million
Book Value$1.46 per share

Profitability

Net Income$-64,790,000.00

Miscellaneous

Employees535
Market Cap$267.15 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.


Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) posted its quarterly earnings results on Monday, February, 10th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.05. The medical research company earned $32.44 million during the quarter, compared to analyst estimates of $32.14 million. Fluidigm had a negative return on equity of 20.31% and a negative net margin of 55.26%. The business's revenue for the quarter was up .4% on a year-over-year basis. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Fluidigm.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm updated its FY 2020 After-Hours earnings guidance on Monday, February, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $126.622-130.14 million, compared to the consensus revenue estimate of $124.85 million.

What price target have analysts set for FLDM?

4 Wall Street analysts have issued 1-year price objectives for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $11.75 in the next year. This suggests a possible upside of 206.0% from the stock's current price. View Analyst Price Targets for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

Media stories about FLDM stock have trended very negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fluidigm earned a news sentiment score of -3.6 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Fluidigm.

Are investors shorting Fluidigm?

Fluidigm saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,060,000 shares, an increase of 18.4% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 3.0% of the shares of the company are sold short. View Fluidigm's Current Options Chain.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (8.42%), Levin Easterly Partners LLC (6.30%), Partner Fund Management L.P. (4.65%), Renaissance Technologies LLC (4.01%), Acadian Asset Management LLC (2.43%) and State Street Corp (2.03%). Company insiders that own Fluidigm stock include Levin Capital Strategies, LP, Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Institutional Ownership Trends for Fluidigm.

Which major investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Levin Easterly Partners LLC, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, AQR Capital Management LLC, Geode Capital Management LLC, Cadence Capital Management LLC and New York State Common Retirement Fund. Company insiders that have sold Fluidigm company stock in the last year include Levin Easterly Partners Llc and Nicolas Barthelemy. View Insider Buying and Selling for Fluidigm.

Which major investors are buying Fluidigm stock?

FLDM stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Parkman Healthcare Partners LLC, Silverback Asset Management LLC, Dupont Capital Management Corp and Partner Fund Management L.P.. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $3.84.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $267.15 million and generates $117.24 million in revenue each year. The medical research company earns $-64,790,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Fluidigm employs 535 workers across the globe.View Additional Information About Fluidigm.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com/.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  496 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  810
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel